Video
Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer
Author(s):
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab (Keytruda).
Most of the patients participating in the study were heavily pre-treated, with the majority being treated in the third-line setting. The combination of ramucirumab plus pembrolizumab was very well tolerated, Chau says, with hardly any treatment-related grade 3 toxicities observed.
In terms of efficacy, though there are only short-term follow-up results as of now, 4 objectives responses were observed, which represents 10% of the patients. Though it may not seem like a high percentage, Chau says, many patients demonstrated prolonged disease stabilization.
At this time, investigators are still waiting for mature data for progression-free survival and overall survival. Those results will help determine how to move forward with future development of the ramucirumab/pembrolizumab combination.
